Article Sidebar
Published:
Nov 20, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Artemisinin ameliorates diabetic retinopathy by upregulating CASC2/miR-155/SIRT1 axis
Abstract
Purpose: To explore the protective effects of artemisinin (Art) against diabetic retinopathy (DR) and the probable mechanism of action.
Methods: MIO-M1 cells were treated with high glucose (HG) and Art, and the cells’ proliferative ability was determined using cell counting kit-8 (CCK-8) and 5-ethynyl-2’-deoxyuridine (EdU) assay. The relative levels of inflammatory factors in the culture medium of MIO-M1 cells were determined by enzyme-linked immunosorbent assay (ELISA). while the expression levels of CASC2, miR-155 and Sirtuin1 (SIRT1) in MIO-M1 cells were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Interaction of Art with the cell target was assessed using dual-luciferase reporter assay. The role of the CASC2/miR-155/SIRT1 axis in Art-induced protection against the proliferation and inflammation of MIO-M1 cells was evaluated.
Results: HG induced elevated proliferation of MIO-M1 cells and production of inflammatory factors, but these effects were countered by Art treatment (p < 0.05). CASC2 and SIRT1 were upregulated, while miR-155 was downregulated in HG-treated MIO-M1 cells; changes in their expressions remained the same following Art treatment. CASC2/miR-155/SIRT1 axis was responsible for the ameliorative effect of Art on HG-treated MIO-M1 cells.
Conclusion: Artemisinin treatment inhibits cell activation and production of pro-inflammatory cytokines in HG-induced MIO-M1 cells via CASC2/miR-155/SIRT1 axis. Thus, artemisinin has potentials for development into a therapeutic agent for the management of diabetic retinopathy.
